

DAFTAR PUSTAKA

- Afrashteh F, Rajabi R 2022. Overview of biomarkers in myasthenia gravis. *Explor Neuroprot Ther*, 2:210-25. doi :10.37349/ent.2022.00029.
- Alanazy MH, Mubarak AM, Abulaban AA, et al. 2019. Clinical features and outcomes of patients with myasthenia gravis. *Neurol Sci*. 40(4):743–751. doi:10.1007/s10072-019-03841-4.
- Alekseeva, T. M., Gavrilov, Y. V., Kreis, O. A., Valko, P. O., Weber, K. P., & Valko, Y. (2018). Fatigue in patients with myasthenia gravis. *Journal of neurology*, 265, 2312-2321.
- Ali, A., Almalki, D., Kotb, M. A., & Alenazi, R. S. (2022). Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City. *Neurosciences Journal*, 27(4), 237-243.
- Andersen JB, et al. 2020. Outcome Measures and Treatment Effectiveness in Late-Onset Myasthenia Gravis. *Neurol Res Pract*.
- Aricha R, Feferman T, Fuchs S, Souroujon MC. 2008. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. *J. Immunol*. 180:2132–9. doi: 10.4049/jimmunol.180.4.2132
- Aricha, R., Reuveni, D., Fuchs, S., & Souroujon, M. C. (2016). Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells. *Journal of Autoimmunity*, 67, 57-64.
- Asberg, A. et al. (2019) 'Measuring calprotectin in plasma and blood with a fully automated turbidimetric assay', *Scandinavian Journal of Clinical and Laboratory Investigation*, 79(1–2), pp. 50–57. doi:10.1080/00365513.2018.1550810.
- Aydemir Bulent, Ersek Siyami. 2016. The effect of Myasthenia Gravis as a prognostic factor in thymoma treatment. *Insanbul*, Turkey.

- Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. 2018 Measuring Clinical Treatment Response in Myasthenia Gravis. *Neurol Clin.* 36(2):339-353. doi: 10.1016/j.ncl.2018.01.006. PMID: 29655453; PMCID: PMC6697147.
- Bolonga J, et al. 2025. Incidence and Prevalence of Juvenile Myasthenia Gravis in the United States (2020). *Adv Ther.*(Springer; klaim dua database).
- Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA 2021. The epidemiology of myasthenia gravis. *J Med Life.*
- Carr AS, Cardwell CR, McCarron PO, McConville J. 2021. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Subtypes (review). *Autoimmune Dis.*(PMCID: PMC8196750). [Bimodal perempuan; peningkatan usia pada laki-laki].
- Carnazzo, V., Redi, S., Basile, V., Natali, P., Gulli, F., Equitani, F., Marino, M. and Basile, U., 2024. *Calprotectin: two sides of the same coin. Rheumatology*, 63(1), pp.26-33.
- Carr AS, Cardwell CR, McCarron PO, McConville J. 2010 A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC Neurol.*10:46.
- Chayanopparat, S., Banyatcharoen, P., Jitprapaikulsan, J., Uawithya, E., Apiraksattayakul, N., & Viarasilpa, V. (2025). Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis. *Scientific Reports*, 15(1), 7219.
- Chen, P. and Tang, X. (2021) 'Gut microbiota as regulators of Th17/Treg balance I patients with myasthenia gravis', *Frontiers in Immunology*, 12. doi:10.3389/fimmu.2021.803101.
- Chen, P. and Tang, X. (2021) 'Gut microbiota as regulators of Th17/Treg balance in patients with myasthenia gravis', *Frontiers in Immunology*, 12. doi:10.3389/fimmu.2021.803101.

- Citirak G, [coauthors]. 2016. Effect of gender, disease duration and treatment on muscle ... *PLOS ONE*. Available from: PLOS ONE database
- Doumiati, H., & Rawas, F. (2024). Myasthenia Gravis: Pathophysiology, Diagnosis, and Management. *IntechOpen*.
- Dresser, L., Wlodarski, R., Rezania, K. and Soliven, B., 2021. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. *Journal of clinical medicine*, 10(11), p.2235.
- Estévez, D. G., Díaz, L. L., Parrado, M. P., Lorenzo, G. P., Casado, N. S., Arteche, G. O., & Gómez, D. R. (2023). Epidemiología de la miastenia gravis en la provincia de Ourense (Galicia, noroeste de España). *Neurologia*, 38(2), 75-81.
- Fichtner, M.L., Jiang, R., Bourke, A., Nowak, R.J. and O'Connor, K.C., 2020. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. *Frontiers in immunology*, 11, p.776
- Gilhus, N.E., Romi, F., Hong, Y. and Skeie, G.O., 2018. Myasthenia gravis and infectious disease. *Journal of neurology*, 265, pp.1251-1258.
- Henry J. K, linda L. Kusner. 2018. Myasthenia Gravis and Related Disorders Third Edition. Humana Press. .189-198
- Herr KJ, Shen S-P, Liu Y, Yang C-C, Tang C-H. 2023. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. *Front Neurol*. 14:1203679. doi:10.3389/fneur.2023.1203679.
- Huang C, et al. 2020. The impact of education level on adherence and quality of life in patients with autoimmune diseases. *Patient Prefer Adherence*.14:1151–1159.
- Howard JF Jr, Utsugisawa K, Benatar M, et al.2021.Safety and efficacy of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol*.20(7):526-536.

Jordan A, Freimer M. 2018. Recent advances in understanding and managing myasthenia gravis. *F1000 Faculty Rev.* 1727:1-6.

Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. 202. *Calprotectin*: from biomarker to biological function. *Gut*. doi: 10.1136/gutjnl-2021-324855. Epub 2021 Jun 18. PMID: 34145045; PMCID: PMC8458070.

Kalita, J., Gutti, N. B., & Ahamed, F. (2025). Outcome Predictors of Generalized Myasthenia Gravis: A Prospective Observational Study. *Annals of Indian Academy of Neurology*, 28(1), 58-65.

Kaminsky HJ, Kusner LL. 2018. *Myasthenia Gravis and Related Disorder* 3rd edition. Washington DC: Humana Press.

KimJ-W, Jung J-Y, Lee S-W et al.(2022) S100A8 in serum, urine, and saliva as a potential biomarker for systemic lupus erythematosus. *Front Immun.*13:886209

Klingberg, E. Strid,H., Stahl. A et al. (2017). A longitudinal study of fecal *calprotectin* and the development of inflammatory bowel disease in ankylosing spondylitis, *Arthritis Res* doi:10.1186/s13075-017-1223-2

Kotsiou, O.S.; Papagiannis, D.; Papadopoulou, R.; Gourgoulisanis, K.I. 2021.*Calprotectin* in Lung Diseases. *Int. J. Mol. Sci.* <https://doi.org/10.3390/ijms22041706>

Liu, P.; Jiang, Y.; Gu, S.; Xue, Y.; Yang, H.; Li, Y.; Wang, Y.; Yan, C.; Jia, P.; Lin, X.; et al.2021 Metagenome-Wide Association Study of Gut Microbiome Revealed Potential Microbial Marker Set for Diagnosis of Pediatric Myasthenia Gravis. *BMC Med.* 19, 159.

Majigoudra, G., Duggal, A.K., Chowdhury, D., Koul, A., Todi, V.K. and Roshan, S., 2023. Clinical Profile and Quality of Life in Myasthenia Gravis Using MGQOL15 R (Hindi): An Indian Perspective. *Annals of Indian Academy of Neurology*, 26(4), pp.441-446.

Manfredi, M. *et al.* (2023) ‘Circulating *calprotectin* (CCLP) in autoimmune diseases’,

Autoimmunity Reviews, 22(5), p. 103295. doi:10.1016/j.autrev.2023.103295.

Mao, Z., Yin, J., Lu, Z., & Hu, X. (2015). Association between myasthenia gravis and cognitive function: A systematic review and meta-analysis. *Annals of Indian Academy of Neurology*, 18(2), 131-137.

Mantegazza R, et al. 2022. Long-term prognosis and outcome predictors in myasthenia gravis: A retrospective cohort study. *J Neurol*. 269(3):1500–1509.

Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., Melms, A., Tackenberg, B., Schalke, B., Schneider-Gold, C. and Zimprich, F., 2016. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. *Journal of neurology*, 263, pp.1473-1494.

Menon, D., Barnett, C. and Brill, V., 2020. Novel treatments in myasthenia gravis. *Frontiers in neurology*, 11, p.538

Miller-Wilson LA, Arackal J, Edwards Y, Schwinn J, Rockstein KE, Venker B, Nowak RJ. 2025. Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database. *BMJ Neurology Open*.23;7(1):e001076..

Moris, G., Arboleya, S., Mancabelli, L., Milani, C., Ventura, M., de Los Reyes-Gavilán, C.G. and Gueimonde, M., 2018. Fecal microbiota profile in a group of myasthenia gravis patients. *Scientific reports*, 8(1), p.14384.

Mukharesh L, Kaminsky HJ. 2019. A neurologist's perspective to understanding myasthenia gravis. *Thorax Surg Clin*.29(2):133-141.

Nessi V, Nava S, Ruocco C, Toscani C, Mantegazza R, Antozzi C, et al. 2010. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. *J Immunol*. 185:5656– 67. doi: 10.4049/jimmunol.0903183

- Nessi, V., Nava, S., Ruocco, C., Toscani, C., Mantegazza, R., Antozzi, C., & Baggi, F. (2010). Naturally occurring CD4⁺ CD25⁺ regulatory T cells prevent but do not improve experimental myasthenia gravis. *The Journal of Immunology*, 185(9), 5656-5667.
- Ometto F, Friso L, Astorri D, Botsios C, Raffener B, Punzi L, Doria A, 2017. *Calprotectin* in rheumatic diseases. *Exp Biol Med (Maywood)*.242(8): 859-873
- Pesa J, Choudry Z, De Courcy J, Barlow S, Gibson G, Chatterton E, Birija SL, Han B, Govindarajan R. 2023. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries. *BMC Neurol*. 12:24(1):385.
- Qiu, D. *et al.* (2018) 'Altered Gut Microbiota in myasthenia gravis', *Frontiers in Microbiology*, 9. doi:10.3389/fmicb.2018.02627.
- Regnault, A. *et al.* (2023) 'Measuring overall severity of myasthenia gravis (MG): Evidence for the added value of the MG symptoms pro', *Neurology and Therapy*, 12(5), pp. 1573–1590. doi:10.1007/s40120-023-00464-x.
- Rodríguez Cruz, P.M., Cossins, J., Beeson, D. and Vincent, A., 2020. The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis. *Frontiers in molecular neuroscience*, 13, p.610964.
- Ruiter, A.M., Verschuuren, J.J. and Tannemaat, M.R., 2021. Prevalence and associated factors of fatigue in autoimmune myasthenia gravis. *Neuromuscular Disorders*, 31(7), pp.612-621.
- Sadeghpour Heravi, F. (2024) 'Gut microbiota and autoimmune diseases: Mechanisms, treatment, challenges, and future recommendations', *Current Clinical Microbiology Reports*, 11(1), pp. 18–33. doi:10.1007/s40588-023-00213-6.

- Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, et al. 2021. International Consensus Guidance for Management of Myasthenia Gravis: 2020 update. *Neurology*;96(3):114–122. (PubMed PMID:33144515).
- Sejersen K, Haverlka A, Sanchez Salas P, Larsson A. 2022. Early Kinetics of calprotectin in plasma following inguinal hernia surgery. *Innate Immun.*
- S. Keovilayhong, A. Mulliez, L. Feral, C. Chenaf, P. Clavelou, X. Moisset, F. Taithe, L. Poncet Megemont, 2024. Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data, *Revue Neurologique*, Volume 180, Issue 5, Pages 451-458
- Stascheit, F., Hotter, B., Hoffmann, S., Kohler, S., Lehnerer, S., Sputtek, A., & Meisel, A. (2021). *Calprotectin* as potential novel biomarker in myasthenia gravis. *Journal of Translational Autoimmunity*, 4. <https://doi.org/10.1016/j.jtauto.2021.100111>
- Stascheit, F., Schulze, D., Lehnerer, S., Gerischer, L., Stein, M., Doksani, P., ... & Meisel, A. (2025). *Calprotectin* and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy—A pilot study. *Journal of Autoimmunity*, 157, 103476.
- St GerMeine-Smith C, et al. 2024. Aging and infectious diseases in myasthenia gravis. *J Theor Biol Med Model*.(Review on age patterns).
- Suyani, Manfaluthy, Mujiani. 2018. Pedoman Tatalaksana GBS, CIDP, MG, Imunoterapi; *Pokdi Neurofisiologi, Perdossi*. Edisi 1.
- Syahrul, S., Mutiawati, E., Astini, N., Fajri, N. and Suherman, S., 2020. Clinical Characteristic Myasthenia Gravis among Indonesians. *Budapest International Research in Exact Sciences (BirEx) Journal*, 2(2), pp.257-263.
- Thye, A.Y.K., Law, J.W.F., Tan, L.T.H., Thuraijasingam, S., Chan, K.G., Letchumanan, V. and Lee, L.H., 2022. Exploring the gut microbiome in myasthenia gravis. *Nutrients*, 14(8), p.1647.

- Totzeck, A., Ramakrishnan, E., Schlag, M., Stolte, B., Kizina, K., Bolz, S., Thimm, A., Stettner, M., Marchesi, J.R., Buer, J. and Kleinschnitz, C., 2021. Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study. *Therapeutic Advances in Neurological Disorders*, 14, p.17562864211035657.
- Tsai NW, [other authors]. 2024.Epidemiology, patient characteristics, and treatment patterns of myasthenia gravis in Taiwan: a population-based and hospital record study. *Neurology and Therapy*. doi:10.1007/s40120-024-00619-4.
- Uzawa, A., Kuwabara, S., Suzuki, S., IMei, T., Murai, H., Ozawa, Y., Yasuda, M., Nagane, Y. and Utsugisawa, K., 2021. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. *Clinical & Experimental Immunology*, 203(3), pp.366-374.
- Wang, Siwen *et al.* (2018) 'S100A8/A9 in inflammation', *Frontiers in Immunology*, 9. doi:10.3389/fimmu.2018.01298.
- Westergaard D, Voss A, Hietala MA, et al. 2024. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden. *J Neurol*.(PMCID: PMC11420710)
- Wu, Y., Luo, J. and Garden, O.A., 2020. Immunoregulatory cells in myasthenia gravis. *Frontiers in Neurology*, 11, p.593431.
- Zhang Y, Wang H. Liu Z.2022. Gender differences in serum *calprotectin* among autoimmune disease patients ; a cross sectional analysis. *Clin. Rheumatol.* 41 (5): 1451-9
- Zhou L, et al.2022.The Spectrum of Myasthenia Gravis: Disease Phenotype, Management and Biomarkers. *Front Neurol*.13:846304.